A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best SupportiveCare Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Phase: Phase II-III clinical trials
Principal Investigator: Dott. Procopio Giuseppe
Main Facility: Oncologia Medica Genitourinaria
Drug: PASRITAMIG (BISPECIFOC KLK-2 / CD3 ANTIBODY)
Pathologies: Prostate tumors
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cellredirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Last update: 20/04/2026